Shilpa Medicare arm to make Sputnik V vaccine
The Hindu
Collaborates with Dr. Reddy’s, exploring option to manufacture Sputnik Lite
Shilpa Medicare has announced a collaboration with Dr. Reddy's Laboratories to produce Sputnik V, the Russian vaccine against COVID-19. Wholly-owned subsidiary Shilpa Biologicals has entered into a three year definitive agreement with Dr. Reddy's to manufacture Sputnik V vaccine from its integrated biologics research and development cum manufacturing centre in Dharwad, Karnataka, Shilpa Medicare said in a regulatory filing on Monday. The targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses (50 million of component 1 and 50 million of component 2), from the date of start of commercial production, the company said.More Related News
Air India has signed an agreement with Bengaluru Airport City Limited (BACL), a subsidiary of Bangalore International Airport Limited (BIAL), to develop a built-to-suit facility for the AME program that will feature modern classrooms, well-equipped laboratories for practical training and a team of qualified trainers.